Context Therapeutics
Context is dedicated to developing the next generation of T cell engaging (TCE) bispecific antibody therapies to treat solid tumors. Our Pipeline Context Therapeutics is building an innovative portfolio of clinical-stage T cell engaging bispecific therapeutics.
News & Media — Context Therapeutics
Kelly Byrnes-Blake, Edward Calamai, Stanley Roberts, and Eric Butz. Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting I Abstract 1288 I November 7-11, 2024
CTIM-76 - Context Therapeutics
Nov 3, 2023 · Context’s lead candidate, CTIM-76, is a CLDN6 x CD3 bispecific antibody that incorporates a highly selective CLDN6 binding arm and a CD3 binding single-chain Fv domain in an IgG format with a silenced Fc that is designed to be functionally monovalent to avoid aberrant T-cell activation and to enhance the safety profile.
Clinical Trial Manager, Clinical Operations — Context Therapeutics
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a ...
SVP, Development — Context Therapeutics
Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody.
Partnering - Context Therapeutics
Selective product in-licensing or acquisition will enable Context Therapeutics to rapidly build a diversified pipeline of T cell engaging bispecific antibodies to treat solid tumors. SOURCE. Academia, startup, or pharma. STAGE. Preclinical development through Phase 2-ready. TYPE. T cell engaging (TCE) bispecific antibody for solid tumors.
Context Therapeutics Reports First Quarter 2024 Operating and …
Dec 31, 2023 · PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and reported on recent business highlights.
Context Therapeutics to Participate in Upcoming Investor …
Oct 23, 2024 · Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody.
Head of Regulatory — Context Therapeutics
As Head of Global Regulatory Affairs, you will oversee and drive the U.S. and Global regulatory strategy and operations for Context Therapeutics. You will partner closely with cross functional leadership, offering regulatory guidance, regulatory risk advice, and leading interactions with regulatory agencies on behalf of Context Therapeutics.
About — Context Therapeutics
Investors & News. Open Menu Close Menu. About Pipeline Patients Careers Investors & News. Our Purpose. Our purpose is what weaves us together. It is the single most important reason we come to work each day. ... CEO, Context Therapeutics. Director and CEO. Independent Director. Linda West. Independent Director. Independent Director. Our Values ...